Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Pharmadrug Inc C.PHRX

Alternate Symbol(s):  LMLLF

PharmaDrug Inc. is a Canada-based specialty pharmaceutical company. The Company is focused on the research, development and commercialization of controlled-substances and natural medicines, such as psychedelics and previously approved drugs. The Company’s subsidiary, Sairiyo Therapeutics (Sairiyo), is a biotech company that specializes in researching and reformulating established natural medicines. Sairiyo is engaged in the development of its patented reformulation of cepharanthine, a drug that has shown substantial third party validated potential for the treatment of infectious diseases (including Covid-19) and rare cancers. In clinical research, Cepharanthine exhibits multiple pharmacological effects, including anti-oxidative, anti-inflammatory, immuno-regulatory, anti-cancer, anti-viral and anti-parasitic properties. Sairiyo is also conducting research and development (R&D) in the psychedelics space for the treatment of non-neuropsychiatric conditions.


CSE:PHRX - Post by User

Post by MIKERRRRon Aug 10, 2020 3:38pm
135 Views
Post# 31389111

FUN FACTS...

FUN FACTS...Wondering what Buzz Pumpers have to say about these facts:

BUZZ, fully diluted, is sitting at 316 Million shares ( see page 14 of their Corporate Presentation )...

Q1 2020 Revenue was $178,000...

Q2 2020 won't be much better ( Report due soon, likely won't break $250,000 Revenue )...

And going forward, even with new supply agreements for Germany cannabis operations, and. a couple new Smart Shops in The Nerherlands on the psychedelic side, the Buzz CEO has made it pretty clear this is a SLOW growing, HIGH risk, completely unproven venture ( we've spoken on the phone, and emailed a couple times )...

Daniel told me himself that the first Smart Shop acquisitions will be SMALL, and that's a conscious decision to work out all the legal details, etc. before bigger moves are made...

So the company will be LUCKY to generate $2M in Revenue for the WHOLE year...

316M shares... Less than $500K in Revenue for the first HALF of 2020...

LONG term ( 2021-22 perhaps ) might look alright for BUZZ, but I don't see ANY justification for the share price to be where it is right now, let alone move up...

The Pharmadrug team might be "glorious", but they've got a TON of work to do before this becomes a viable, profitable business... 
<< Previous
Bullboard Posts
Next >>